GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
GATA2
Prostate cancer
SMAD4
TGFβ1
rs339331
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
21
01
2023
accepted:
30
06
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Aberrant somatic genomic alteration including copy number amplification is a hallmark of cancer genomes. We previously profiled genomic landscapes of prostate cancer (PCa), yet the underlying causal genes with prognostic potential has not been defined. It remains unclear how a somatic genomic event cooperates with inherited germline variants contribute to cancer predisposition and progression. We applied integrated genomic and clinical data, experimental models and bioinformatic analysis to identify GATA2 as a highly prevalent metastasis-associated genomic amplification in PCa. Biological roles of GATA2 in PCa metastasis was determined in vitro and in vivo. Global chromatin co-occupancy and co-regulation of GATA2 and SMAD4 was investigated by coimmunoprecipitation, ChIP-seq and RNA-seq assays. Tumor cellular assays, qRT-PCR, western blot, ChIP, luciferase assays and CRISPR-Cas9 editing methods were performed to mechanistically understand the cooperation of GATA2 with SMAD4 in promoting TGFβ1 and AR signaling and mediating inherited PCa risk and progression. In this study, by integrated genomics and experimental analysis, we identified GATA2 as a prevalent metastasis-associated genomic amplification to transcriptionally augment its own expression in PCa. Functional experiments demonstrated that GATA2 physically interacted and cooperated with SMAD4 for genome-wide chromatin co-occupancy and co-regulation of PCa genes and metastasis pathways like TGFβ signaling. Mechanistically, GATA2 was cooperative with SMAD4 to enhance TGFβ and AR signaling pathways, and activated the expression of TGFβ1 via directly binding to a distal enhancer of TGFβ1. Strinkingly, GATA2 and SMAD4 globally mediated inherited PCa risk and formed a transcriptional complex with HOXB13 at the PCa risk-associated rs339331/6q22 enhancer, leading to increased expression of the PCa susceptibility gene RFX6. Our study prioritizes causal genomic amplification genes with prognostic values in PCa and reveals the pivotal roles of GATA2 in transcriptionally activating the expression of its own and TGFβ1, thereby co-opting to TGFβ1/SMAD4 signaling and RFX6 at 6q22 to modulate PCa predisposition and progression.
Sections du résumé
BACKGROUND
BACKGROUND
Aberrant somatic genomic alteration including copy number amplification is a hallmark of cancer genomes. We previously profiled genomic landscapes of prostate cancer (PCa), yet the underlying causal genes with prognostic potential has not been defined. It remains unclear how a somatic genomic event cooperates with inherited germline variants contribute to cancer predisposition and progression.
METHODS
METHODS
We applied integrated genomic and clinical data, experimental models and bioinformatic analysis to identify GATA2 as a highly prevalent metastasis-associated genomic amplification in PCa. Biological roles of GATA2 in PCa metastasis was determined in vitro and in vivo. Global chromatin co-occupancy and co-regulation of GATA2 and SMAD4 was investigated by coimmunoprecipitation, ChIP-seq and RNA-seq assays. Tumor cellular assays, qRT-PCR, western blot, ChIP, luciferase assays and CRISPR-Cas9 editing methods were performed to mechanistically understand the cooperation of GATA2 with SMAD4 in promoting TGFβ1 and AR signaling and mediating inherited PCa risk and progression.
RESULTS
RESULTS
In this study, by integrated genomics and experimental analysis, we identified GATA2 as a prevalent metastasis-associated genomic amplification to transcriptionally augment its own expression in PCa. Functional experiments demonstrated that GATA2 physically interacted and cooperated with SMAD4 for genome-wide chromatin co-occupancy and co-regulation of PCa genes and metastasis pathways like TGFβ signaling. Mechanistically, GATA2 was cooperative with SMAD4 to enhance TGFβ and AR signaling pathways, and activated the expression of TGFβ1 via directly binding to a distal enhancer of TGFβ1. Strinkingly, GATA2 and SMAD4 globally mediated inherited PCa risk and formed a transcriptional complex with HOXB13 at the PCa risk-associated rs339331/6q22 enhancer, leading to increased expression of the PCa susceptibility gene RFX6.
CONCLUSIONS
CONCLUSIONS
Our study prioritizes causal genomic amplification genes with prognostic values in PCa and reveals the pivotal roles of GATA2 in transcriptionally activating the expression of its own and TGFβ1, thereby co-opting to TGFβ1/SMAD4 signaling and RFX6 at 6q22 to modulate PCa predisposition and progression.
Identifiants
pubmed: 37550764
doi: 10.1186/s13046-023-02745-7
pii: 10.1186/s13046-023-02745-7
pmc: PMC10408074
doi:
Substances chimiques
Transforming Growth Factor beta
0
Chromatin
0
SMAD4 protein, human
0
Smad4 Protein
0
GATA2 protein, human
0
GATA2 Transcription Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 82073082
Informations de copyright
© 2023. Italian National Cancer Institute ‘Regina Elena’.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361(9361):955–64.
pubmed: 12648986
doi: 10.1016/S0140-6736(03)12779-1
Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, et al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014;21(4):T105–118.
pubmed: 24639562
doi: 10.1530/ERC-13-0545
Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967–2000.
pubmed: 20844012
pmcid: 2939361
doi: 10.1101/gad.1965810
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
pubmed: 20579941
pmcid: 3198787
doi: 10.1016/j.ccr.2010.05.026
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–51.
pubmed: 29610475
pmcid: 6107367
doi: 10.1038/s41588-018-0078-z
Cancer Genome Atlas Research N. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011–25.
doi: 10.1016/j.cell.2015.10.025
Li J, Xu C, Lee HJ. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–9.
pubmed: 32238934
doi: 10.1038/s41586-020-2135-x
Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA. 2014;111(30):11139–44.
pubmed: 25024180
pmcid: 4121784
doi: 10.1073/pnas.1411446111
Wang X, Grasso CS, Jordahl KM, Kolb S, Nyame YA, Wright JL, et al. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(3):494–506.
pubmed: 32071439
pmcid: 7725282
doi: 10.1038/s41391-020-0212-8
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436(7047):117–22.
pubmed: 16001072
doi: 10.1038/nature03664
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
pubmed: 20164920
pmcid: 2826709
doi: 10.1038/nature08822
Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, et al. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol. 2018;73(3):322–39.
pubmed: 28927585
doi: 10.1016/j.eururo.2017.08.027
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016;6(8):914–29.
pubmed: 27260156
pmcid: 4972686
doi: 10.1158/2159-8290.CD-16-0154
Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol. 2017;14(1):38–48.
pubmed: 27872477
doi: 10.1038/nrurol.2016.225
Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019;19(11):611–24.
pubmed: 31511663
pmcid: 8820243
doi: 10.1038/s41568-019-0196-7
Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27(3):380–92.
pubmed: 17679089
pmcid: 3947890
doi: 10.1016/j.molcel.2007.05.041
Bohm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene. 2009;28(43):3847–56.
pubmed: 19684615
doi: 10.1038/onc.2009.243
Hankey W, Chen Z, Wang Q. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors. Can Res. 2020;80(12):2427–36.
doi: 10.1158/0008-5472.CAN-19-3447
He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci USA. 2014;111(51):18261–6.
pubmed: 25489091
pmcid: 4280633
doi: 10.1073/pnas.1421415111
Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 2014;42(6):3607–22.
pubmed: 24423874
pmcid: 3973339
doi: 10.1093/nar/gkt1382
Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, et al. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic acids research 2019, 47(19).
Matos B, Howl J, Jerónimo C, Fardilha M. The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer. Pharmacol Res. 2020;161:105145.
pubmed: 32814172
doi: 10.1016/j.phrs.2020.105145
Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009;13(2):227–34.
pubmed: 19236240
doi: 10.1517/14728220802705696
Massague J. TGFbeta in Cancer. Cell. 2008;134(2):215–30.
pubmed: 18662538
pmcid: 3512574
doi: 10.1016/j.cell.2008.07.001
Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009;19(1):89–102.
pubmed: 19050696
doi: 10.1038/cr.2008.316
McCarthy AJ, Chetty R. Smad4/DPC4. J Clin Pathol. 2018;71(8):661–4.
pubmed: 29720405
doi: 10.1136/jclinpath-2018-205095
Wrana JL. The secret life of Smad4. Cell. 2009;136(1):13–4.
pubmed: 19135880
doi: 10.1016/j.cell.2008.12.028
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470(7333):269–73.
pubmed: 21289624
pmcid: 3753179
doi: 10.1038/nature09677
Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, et al. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature. 2013;493(7431):236–40.
pubmed: 23201680
doi: 10.1038/nature11674
Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, et al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis. J Clin Investig. 2014;124(2):564–79.
pubmed: 24382352
pmcid: 3904622
doi: 10.1172/JCI71104
Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788–99.
pubmed: 24132110
pmcid: 4025940
doi: 10.1038/nrc3603
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;3(2):78–85.
doi: 10.1056/NEJM200007133430201
Tian P, Zhong M, Wei GH. Mechanistic insights into genetic susceptibility to prostate cancer. Cancer Lett. 2021;522:155–63.
pubmed: 34560228
doi: 10.1016/j.canlet.2021.09.025
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928–36.
pubmed: 29892016
pmcid: 6568012
doi: 10.1038/s41588-018-0142-8
Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103–9.
pubmed: 25217961
pmcid: 4383163
doi: 10.1038/ng.3094
Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53(1):65–75.
pubmed: 33398198
pmcid: 8148035
doi: 10.1038/s41588-020-00748-0
Cowper-Sal lari R, Zhang X, Zhang X, Wright JB, Bailey SD, Cole MD, et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet. 2012;44(11):1191–8.
pubmed: 23001124
pmcid: 3483423
doi: 10.1038/ng.2416
Schodel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet. 2012;44(4):420–5 S421–422.
pubmed: 22406644
pmcid: 3378637
doi: 10.1038/ng.2204
Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, et al. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat Genet. 2014;46(2):126–35.
pubmed: 24390282
doi: 10.1038/ng.2862
Gao P, Xia JH, Sipeky C, Dong XM, Yang Y, et al. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell. 2018;174(3):576–589.e518.
pubmed: 30033361
pmcid: 6091222
doi: 10.1016/j.cell.2018.06.003
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.
pubmed: 24695404
pmcid: 4103590
doi: 10.1093/bioinformatics/btu170
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Kuhn RM, Haussler D, Kent WJ. The UCSC genome browser and associated tools. Brief Bioinform. 2013;14(2):144–61.
pubmed: 22908213
doi: 10.1093/bib/bbs038
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
pubmed: 21221095
pmcid: 3346182
doi: 10.1038/nbt.1754
Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576–89.
pubmed: 20513432
pmcid: 2898526
doi: 10.1016/j.molcel.2010.05.004
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841–2.
pubmed: 20110278
pmcid: 2832824
doi: 10.1093/bioinformatics/btq033
Zhu LJ, Gazin C, Lawson ND, Pagès H, Lin SM, Lapointe DS, et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 2010, 11(1).
Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2 a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 2016;44(W1):W160–165.
pubmed: 27079975
pmcid: 4987876
doi: 10.1093/nar/gkw257
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–9.
pubmed: 25260700
doi: 10.1093/bioinformatics/btu638
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27(12): 1739–1740.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Zuo C, Shin S, Keles S. atSNP: transcription factor binding affinity testing for regulatory SNP detection. Bioinformatics. 2015;31(20):3353–5.
pubmed: 26092860
pmcid: 4643619
doi: 10.1093/bioinformatics/btv328
Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res. 2014;42(5):2976–87.
pubmed: 24335146
doi: 10.1093/nar/gkt1249
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298–305.
pubmed: 26855148
pmcid: 4777652
doi: 10.1038/nm.4045
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–90.
pubmed: 23091115
doi: 10.1158/1078-0432.CCR-12-1558
Cui Y, Chen X, Luo H, Fan Z, Luo J, He S, et al. BioCircos.js: an interactive Circos JavaScript library for biological data visualization on web applications. Bioinformatics 2016, 32(11): 1740–1742.
Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, et al. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol. 2017;13(2):914.
pubmed: 28202506
pmcid: 5327725
doi: 10.15252/msb.20167159
Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, et al. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014;5(2):451–61.
pubmed: 24448395
pmcid: 3964220
doi: 10.18632/oncotarget.1296
Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, et al. GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol. 2017;90(1075):20170174.
pubmed: 28486040
pmcid: 5594993
doi: 10.1259/bjr.20170174
Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, et al. Cistrome Data Browser expanded datasets and new tools for gene regulatory analysis. Nucleic acids research 2019, 47(D729–D735).
Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39(3):311–8.
pubmed: 17277777
doi: 10.1038/ng1966
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–19.
pubmed: 23582322
pmcid: 3653129
doi: 10.1016/j.cell.2013.03.035
Li Y, Gao J, Kamran M, Harmacek L, Danhorn T, Leach SM, et al. GATA2 regulates mast cell identity and responsiveness to antigenic stimulation by promoting chromatin remodeling at super-enhancers. Nat Commun. 2021;12(1):494.
pubmed: 33479210
pmcid: 7820599
doi: 10.1038/s41467-020-20766-0
Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, et al. Cistrome Data Browser expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47(D1):D729–35.
pubmed: 30462313
doi: 10.1093/nar/gky1094
Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, et al. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Res. 2016;44(9):4105–22.
pubmed: 26743006
pmcid: 4872073
doi: 10.1093/nar/gkv1528
Itkonen HM, Urbanucci A, Martin SE, Khan A, Mathelier A, Thiede B, et al. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. Theranostics. 2019;9(8):2183–97.
pubmed: 31149037
pmcid: 6531294
doi: 10.7150/thno.30834
Yan Ting Chiang KW, Ladan Fazli, Robert Z. Qi, Martin E. Gleave,Colin C. Collins, Peter W. Gout, Yuzhuo Wang. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 2014, 5(2): 451–461.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119(6):1420–8.
pubmed: 19487818
pmcid: 2689101
doi: 10.1172/JCI39104
Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg. EMBO J. 2017;36(23):3409–20.
pubmed: 29127156
pmcid: 5709748
doi: 10.15252/embj.201796438
Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–14.
pubmed: 19440234
pmcid: 2722839
doi: 10.1038/nrc2657
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222–34.
pubmed: 29460925
pmcid: 7472658
doi: 10.1038/nrurol.2018.9
Melegh Z, Oltean S. Targeting Angiogenesis in Prostate Cancer. International journal of molecular sciences 2019, 20(11).
Zhu QQ, Ma C, Wang Q, Song Y, Lv T. The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(1):185–97.
pubmed: 26602382
doi: 10.1007/s13277-015-4450-7
Alanis-Lobato G, Andrade-Navarro MA, Schaefer MH. HIPPIE v2.0: enhancing meaningfulness and reliability of protein-protein interaction networks. Nucleic acids research 2017, 45(D1): D408-D414.
Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 2019;47(D1):D581–9.
pubmed: 30407591
doi: 10.1093/nar/gky1037
Basha O, Barshir R, Sharon M, Lerman E, Kirson BF, Hekselman I, et al. The TissueNet vol 2 database: A quantitative view of protein-protein interactions across human tissues. Nucleic Acids Res. 2017;45(D1):D427–31.
pubmed: 27899616
doi: 10.1093/nar/gkw1088
Luck K, Kim D-K, Lambourne L, Spirohn K, Begg BE, Bian W, et al. A reference map of the human binary protein interactome. Nature. 2020;580(7803):402–8.
pubmed: 32296183
pmcid: 7169983
doi: 10.1038/s41586-020-2188-x
Dong XM, Yin RH, Yang Y, Feng ZW, Ning HM, Dong L, et al. GATA-2 inhibits transforming growth factor-beta signaling pathway through interaction with Smad4. Cell Signal. 2014;26(5):1089–97.
pubmed: 24509415
doi: 10.1016/j.cellsig.2014.01.028
Colak S, Ten Dijke P. Targeting TGF-beta Signaling in Cancer. Trends in cancer. 2017;3(1):56–71.
pubmed: 28718426
doi: 10.1016/j.trecan.2016.11.008
Seoane J, Gomis RR. TGF-beta Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harbor perspectives in biology 2017, 9(12).
L Zawel JLD, P Buckhaults, S Zhou, K W Kinzler, B Vogelstein, S E Kern. Human Smad3 and Smad4 are sequence-specific transcription activators. Molecular cell 1998, 1: 611–617.
Wang Y, Song F, Zhang B, Zhang L, Xu J, Kuang D, et al. The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Genome Biol. 2018;19(1):151.
pubmed: 30286773
pmcid: 6172833
doi: 10.1186/s13059-018-1519-9
Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc. 2007;2(7):1722–33.
pubmed: 17641637
doi: 10.1038/nprot.2007.243
Yan J, Qiu Y. Systematic analysis of binding of transcription factors to noncoding variants. Nature. 2021;591(7848):147–51.
pubmed: 33505025
pmcid: 9367673
doi: 10.1038/s41586-021-03211-0
Deplancke B, Alpern D, Gardeux V. The Genetics of Transcription Factor DNA Binding Variation. Cell. 2016;166(3):538–54.
pubmed: 27471964
doi: 10.1016/j.cell.2016.07.012
Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.
doi: 10.1038/ng.2653
Gong J, Mei S, Liu C, Xiang Y, Ye Y, Zhang Z, et al. PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Res. 2018;46(D1):D971–6.
pubmed: 29036324
doi: 10.1093/nar/gkx861
Li J, Xue Y, Amin MT, Yang Y, Yang J, Zhang W, et al. ncRNA-eQTL: a database to systematically evaluate the effects of SNPs on non-coding RNA expression across cancer types. Nucleic Acids Res. 2020;48(D1):D956–63.
pubmed: 31410488
doi: 10.1093/nar/gkz711
Spisak S, Lawrenson K, Fu Y, Csabai I, Cottman RT, Seo JH, et al. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med. 2015;21(11):1357–63.
pubmed: 26398868
pmcid: 4746056
doi: 10.1038/nm.3975
Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, et al. Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat Genet. 2016;48(4):387–97.
pubmed: 26950096
doi: 10.1038/ng.3523
Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell. 2015;27(2):223–39.
pubmed: 25670080
pmcid: 4356948
doi: 10.1016/j.ccell.2014.11.013
Billing M, Rorby E, May G, Tipping AJ, Soneji S, Brown J, et al. A network including TGFbeta/Smad4, Gata2, and p57 regulates proliferation of mouse hematopoietic progenitor cells. Exp Hematol. 2016;44(5):399–409.e395.
pubmed: 26876150
doi: 10.1016/j.exphem.2016.02.001
Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37(1):19–29.
pubmed: 9721065
doi: 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3
Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 2014;33(2–3):413–27.
pubmed: 24384911
doi: 10.1007/s10555-013-9474-0
Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011;29(27):3651–8.
pubmed: 21859989
doi: 10.1200/JCO.2011.35.2005
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465–74.
pubmed: 29949494
pmcid: 8288034
doi: 10.1056/NEJMoa1800536
Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ, Kyprianou N. TGF-beta receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate. 2019;79(1):31–43.
pubmed: 30155899
doi: 10.1002/pros.23708
Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, et al. Targeting FOXA1-mediated repression of TGF-beta signaling suppresses castration-resistant prostate cancer progression. J Clin Investig. 2019;129(2):569–82.
pubmed: 30511964
doi: 10.1172/JCI122367
Giannareas N, Zhang Q, Yang X, Na R. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG. Nat Commun. 2022;13(1):7320.
pubmed: 36443337
pmcid: 9705428
doi: 10.1038/s41467-022-34994-z
Dai H, Chu X, Liang Q, Wang M, Li L, Zhou Y, et al. Genome-wide association and functional interrogation identified a variant at 3p26.1 modulating ovarian cancer survival among Chinese women. Cell Discov. 2021;7(1):121.
pubmed: 34930913
pmcid: 8688503
doi: 10.1038/s41421-021-00342-6
Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nat Rev Cancer. 2019;19(1):46–59.
pubmed: 30538273
doi: 10.1038/s41568-018-0087-3
Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer. 2017;17(11):692–704.
pubmed: 29026206
doi: 10.1038/nrc.2017.82
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci signal. 2013;6(269):pl1.
pubmed: 23550210
pmcid: 4160307
doi: 10.1126/scisignal.2004088
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–995.
pubmed: 23193258
Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.
pubmed: 11752295
pmcid: 99122
doi: 10.1093/nar/30.1.207
Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005–12.
pubmed: 30445434
doi: 10.1093/nar/gky1120